半年暴涨近5倍！知名药企拟回A股上市

Core Viewpoint - After six months of being listed on the Hong Kong Stock Exchange, the company plans to return to the A-share Sci-Tech Innovation Board for a new listing, subject to market conditions and necessary approvals [2]. Group 1: Company Overview - The company was founded by Zhu Zhongyuan, a veteran in the biotechnology industry with over 20 years of experience in biotech entrepreneurship and venture capital [4]. - The company officially listed on the Hong Kong Stock Exchange on April 15, 2025, raising approximately $243 million, marking one of the largest IPOs in the Hong Kong market in recent years [4]. - The initial offering price was HKD 94.6 per share, with a significant increase of 116.7% on the first trading day [4]. Group 2: Stock Performance - The company's stock price peaked at HKD 563.5 in September, representing a maximum increase of 495.67% since its IPO [3][4]. - As of October 17, the stock closed at HKD 334.2, giving the company a market capitalization of HKD 29.4 billion [4]. Group 3: Financial Performance - The company reported revenues of CNY 1.6 million, CNY 1.787 billion, and CNY 1.941 billion for the years 2022 to 2024, primarily from upfront and milestone payments for product licensing [7]. - The net losses for the same period were CNY -387 million, CNY -358 million, and CNY -1.05 billion, indicating a trend of increasing losses [7]. - In the first half of 2025, the company generated revenues of CNY 1.229 billion but reported a loss of CNY 2.074 billion, nearly double the loss from 2024 [6][7].